Kaitlyn D’Onofrio

DocwireNews

<a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/patients-with-rheumatoid-arthritis-at-greater-risk-of-covid-19-hospitalization-and-death/">Patients with rheumatoid arthritis (RA) have an increased risk of contracting COVID-19</a>, as well as hospitalization and death associated with the virus, according to a study. Per the researchers&rsquo; adjusted analyses, patients with RA, compared to those without RA, were at a greater risk of COVID-19 and COVID-19 hospitalization or death. Factors associated with COVID-19 and COVID-19 hospitalization or death included disease-modifying antirheumatic drugs, prednisone, Black race, Hispanic ethnicity, and certain chronic conditions. The researchers noted, however, that RA autoantibody seropositivity did not increase the risks of COVID-19 or severe COVID-19.Another study found that <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/patient-characteristics-at-diagnosis-may-predict-10-year-psoriasis-disease-course/">early identification of certain patient factors</a> may predict long-term outcomes in psoriasis. Patients with psoriasis who had plaque phenotype, above-median disease activity, and scalp lesions were much more likely to have severe skin disease. Similarly, patients with initial joint pain were more likely than those without to have psoriatic arthritis after 10 years. Other predictors of severe disease were smoking and activating genes in the IL-23 pathway. Meanwhile, patients with systemic therapy at or before enrolling in the study had a lower 10-year risk of severe disease as opposed to delayed therapy initiation.Finally, <a href="https://www.docwirenews.com/condition-center/orthopedicscc/orthopedics-center-picks/mifamurtide-added-to-osteosarcoma-therapy-may-improve-outcomes/">the addition of mifamurtide to conventional therapy improved</a> progression-free survival (PFS) in patients with osteosarcoma, according to a study. Adverse events were in line with what researchers expected, and they did not observe any dose limiting toxicities or local relapses. Two patients died, one in the first complete remission due to doxorubicin cardiotoxicity, and another to pulmonary metastatic relapse. Three-year event-free survival (EFS) was 87.4%, PFS was 92.9%, and overall survival (OS) was 94.1%. Five-year EFS was 87.4%, PFS was 92.9%, and OS was 80.7%.In Case You Missed It:<a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/patients-with-rheumatoid-arthritis-at-greater-risk-of-covid-19-hospitalization-and-death/">Patients with Rheumatoid Arthritis At Greater Risk of COVID-19, Hospitalization and Death</a><a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/patient-characteristics-at-diagnosis-may-predict-10-year-psoriasis-disease-course/">Patient Characteristics at Diagnosis May Predict 10-Year Psoriasis Disease Course</a><a href="https://www.docwirenews.com/condition-center/orthopedicscc/orthopedics-center-picks/mifamurtide-added-to-osteosarcoma-therapy-may-improve-outcomes/">Mifamurtide Added to Osteosarcoma Therapy May Improve Outcomes</a>

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Latest News

Rheum Round-up: RA Increases Risk of COVID-19, Hospitalization, Death; Predicting PsO Outcomes; and more

Rheumatology

Patients with rheumatoid arthritis (RA) have an increased risk of contracting COVID-19, as well as hospitalization and death associated with the virus, according to a study. ...

Rheum Round-up: RA Increases Risk of COVID-19, Hospitalization, Death; Predicting PsO Outcomes; and

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe